Revenue + Forward P/E
Axsome Therapeutics, Inc. (AXSM) quarterly revenue and forward P/EForward P/E: 740.8x
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$11.20B
Enterprise value
$12.25B
P/E ratio (TTM)
-64.24x
P/S ratio (TTM)
17.41x
P/B ratio
224.74x
EV/Sales
17.29x
EV/EBITDA
-70.90x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$638.50M
Gross profit (TTM)
$591.02M
Operating income (TTM)
$-169.23M
EBITDA (TTM)
$-168.08M
Net income (TTM)
$-183.17M
Free cash flow (TTM)
$-93.88M
Margins & returns
Gross margin
92.60%
Operating margin
-24.80%
Profit margin
-26.59%
Return on equity
-260.01%
Return on assets
-26.39%
Per-share metrics
EPS (TTM)
-$3.68
Dividend yield
0.00%
Beta
0.60
Capital structure
Cash & equivalents
$322.93M
Total debt
$241.29M
Net debt
$-81.64M
Shares outstanding
51.46M
Financial health
Current ratio
1.55
Debt / equity
2.73
Debt / assets
0.35
Interest coverage
-25.81
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.91B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.10B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.06B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.91B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $11.20B | -64.24x | 17.41x | -70.90x | - |